The binding site of aminergic G protein-coupled receptors: The transmembrane segments and second extracellular loop

Annual Review of Pharmacology and Toxicology

Volumn 42, Issue , 2002, Pages 437-467

  Shi, Lei ^a   Javitch, Jonathan A ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

Affinity labeling; Allosteric modulation; Site directed mutagenesis; Specificity; Sulfhydryl

Indexed keywords

G PROTEIN COUPLED RECEPTOR; THIOL DERIVATIVE;

AFFINITY LABELING; ALLOSTERISM; AMINO ACID SEQUENCE; BINDING SITE; DRUG RECEPTOR BINDING; HYDROGEN BOND; LIGAND BINDING; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR AFFINITY; REVIEW; SITE DIRECTED MUTAGENESIS;

AFFINITY LABELS; ANIMALS; BINDING SITES; CELL MEMBRANE; GTP-BINDING PROTEINS; HUMANS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; RECEPTORS, CELL SURFACE;

EID: 0036169280     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.42.091101.144224     Document Type: Review

References (161)

1. GPCRDB: An information system for G protein-coupled receptors
2. Crystal structure of rhodopsin: A G protein-coupled receptor
3. Structural mimicry in G-proteincoupled receptors: Implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsinlike receptors
4. Integrated methods for the construction of three-dimensional models of structurefunction relations in G protein-coupled receptors
5. Acetylcholine mustard labels the binding site aspartate in muscarinic acetylcholine receptors
6. Muscarinic acetylcholine receptors. Peptide sequencing identifies residues involved in antagonist binding and disulfide bond formation
7. The catecholamine binding site of the beta-adrenergic receptor is formed by juxtaposed membrane- spanning domains
8. Antipeptide antibodies localize N-(4-azido-3-[1251] iodophenethyl)spiperone binding to the carboxyl-terminal portion of the D2 dopamine receptor
9. Identification and sequence of a binding site peptide of the beta 2-adrenergic receptor
10. Localization of the fourth membrane spanning domain as a ligand binding site in the human platelet alpha 2-adrenergic receptor
11. Chloroethylclonidine and 2-aminoethyl methanethiosulfonate recognize two different conformations of the human alpha(2A)-adrenergic receptor
12. Chloroethylclonidine binds irreversibly to exposed cysteines in the fifth membrane-spanning domain of the human alpha2A-adrenergic receptor
13. Scanning mutagenesis identifies amino acid side chains in transmembrane domain 5 of the M(1) muscarinic receptor that participate in binding the acetyl methyl group of acetylcholine
14. A highly conserved aspartic acid (Asp155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism
15. Structural basis for sugar translocation through maltoporin channels at 3.1 Å resolution
16. Electrostatic and aromatic microdomains within the binding-site crevice of the D2 receptor: Contributions of the second membrane-spanning segment
17. Pivotal role for aspartate-80 in the regulation of dopamine D2 receptor affinity for drugs and inhibition of adenylyl cyclase
18. Site-directed mutagenesis of the serotonin 5-hydroxytryptamine2 receptor: Identification of amino acids necessary for ligand binding and receptor activation
19. Dopamine D4/D2 receptor selectivity is determined by a divergent aromatic microdomain contained within the second, third, and seventh membrane-spanning segments
20. Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology
21. Phenylalanine in the second membrane-spanning domain of alpha 1A- adrenergic receptor determines subtype selectivity of dihydropyridine antagonists
22. Mutagenesis of 5-HT2 serotonin receptors: What does an analysis of many mutant receptors tell us?
23. Probing of the location of the allosteric site on ml muscarinic receptors by sitedirected mutagenesis
24. The functional topography of transmembrane domain 3 of the M1 muscarinic acetylcholine receptor, revealed by scanning mutagenesis
25. Identification of residues in transmembrane regions III and VI that contribute to the ligand binding site of the serotonin 5-HT6 receptor
26. The functional role of the binding site aspartate in muscarinic acetylcholine receptors, probed by site-directed mutagenesis
27. Site-directed mutagenesis of the putative human muscarinic M2 receptor binding site
28. Identification of residues required for ligand binding to the beta-adrenergic receptor
29. Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function
30. Allele-specific activation of genetically engineered receptors
31. Unique binding pocket for KW-4679 in the histamine H1 receptor
32. Site-directed mutagenesis of the histamine H1 receptor: Roles of aspartic acid107, asparagine198 and threonine194
33. Mapping the binding-site crevice of the dopamine D2 receptor by the substituted-cysteine accessibility method
34. Contributions of cysteine 114 of the human D3 dopamine receptor to ligand binding and sensitivity to external oxidizing agents
35. Differentiating dopamine D2 ligands by their sensitivities to modification of the cysteine exposed in the binding-site crevice
36. Distinct pharmacology of rat and human histamine H(3) receptors: Role of two amino acids in the third transmembrane domain
37. The fourth transmembrane segment of the dopamine D2 receptor: Accessibility in the binding-site crevice and position in the transmembrane bundle
38. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor
39. Mutational analysis of the antagonist-binding site of the histamine H(1) receptor
40. Functional role of proline and tryptophan residues highly conserved among G protein-coupled receptors studied by mutational analysis of the m3 muscarinic receptor
41. Residues in the fifth membrane-spanning segment of the dopamine D2 receptor exposed in the binding-site crevice
42. Roles of threonine 192 and asparagine 382 in agonist and antagonist interactions with M1 muscarinic receptors
43. The forgotten serine. A critical role for Ser-203(5.42) in ligand binding to and activation of the beta 2-adrenergic receptor
44. Pharmacological and functional characterisation of the wild-type and site-directed mutants of the human H1 histamine receptor stably expressed in CHO cells
45. Molecular basis for the interaction of histamine with the histamine H2 receptor
46. Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor
47. Serine mutations in transmembrane V of the dopamine D1 receptor affect ligand interactions and receptor activation
48. Site-directed mutagenesis of a single residue changes the binding properties of the serotonin 5-HT2 receptor from a human to a rat pharmacology
49. Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: Direct and indirect effects on ligand affinity mediated by the same locus
50. Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines
51. Interaction of tryptamine and ergoline compounds with threonine 196 in the ligand binding site of the 5-hydroxytryptamine6 receptor
52. Site-directed mutagenesis of the histamine H1-receptor reveals a selective interaction of asparagine207 with subclasses of H1receptor agonists
53. Differential modes of agonist binding to 5-Hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5
54. A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice
55. Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2A receptors
56. Identification of an amino acid residue important for binding of methiothepin and sumatriptan to the human 5-HT(1B) receptor
57. Alanine-scanning mutagenesis of transmembrane domain 6 of the M(1) muscarinic acetylcholine receptor suggests that Tyr381 plays key roles in receptor function
58. Hydrophobic residues of the D2 dopamine receptor are important for binding and signal transduction
59. A single point mutation (Phe340>Leu340) of a conserved phenylalanine abolishes 4-[125I]iodo-(2,5-dimethoxy) phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxytryptamine2 receptors
60. Differential ergoline and ergopeptine binding to 5-hydroxytryptamine2A receptors: Ergolines require an aromatic residue at position 340 for high affinity binding
61. Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic acetylcholine receptors
62. Mutagenesis of the human 5-HT1B receptor: Differences from the closely related 5-HT1A receptor and the role of residue F331 in signal transduction
63. Study of interaction between agonists and asn293 in helix VI of human beta(2)-adrenergic receptor
64. Structural studies on D2 dopamine receptors: Mutation of a histidine residue specifically affects the binding of a subgroup of substituted benzamide drugs
65. Mapping of dopamine D3 receptor binding site by pharmacological characterization of mutants expressed in CHO cells with the Semliki Forest virus system
66. The role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005
67. Site-directed mutagenesis of the m3 muscarinic receptor: Identification of a series of threonine and tyrosine residues involved in agonist but not antagonist binding
68. A point mutation in the seventh hydrophobic domain of the alpha 2 adrenergic receptor increases its affinity for a family of beta receptor antagonists
69. Amino acid substitutions at position 312 in the seventh hydrophobic segment of the beta 2-adrenergic receptor modify ligand-binding specificity
70. Identification of a single amino acid residue responsible for the binding of a class of beta-adrenergic receptor antagonists to 5-hydroxytryptaminelA receptors
71. Study of the interaction between aryloxypropanolamines and Asn386 in helix VII of the human 5-hydroxytryptamine 1A receptor
72. A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors
73. The binding of propranolol at 5-hydroxytryptamine1D beta T355N mutant receptors may involve formation of two hydrogen bonds to asparagine
74. A single amino acid difference accounts for the pharmacological distinctions between the rat and human 5-hydroxytryptaminelB receptors
75. Site-directed mutagenesis of the rat ml muscarinic acetylcholine receptor. Role of conserved cysteines in receptor function
76. Site-directed mutagenesis of Tyr417 in the rat D2 dopamine receptor
77. Residues in the seventh membrane-spanning segment of the dopamine D2 receptor accessible in the binding-site crevice
78. Contributions of conserved serine residues to the interactions of ligands with dopamine D2 receptors
79. Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor
80. Double mutant cycle analysis of aspartate 69, 97, and 103 to asparagine mutants in the m2 muscarinic acetylcholine receptor
81. The role of conserved aspartate and serine residues in ligand binding and in function of the 5-HT1A receptor: A site-directed mutation study
82. Amino acids of the alpha1B-adrenergic receptor involved in agonist binding: Differences in docking catecholamines to receptor subtypes
83. Mapping the binding site pocket of the serotonin 5-hydroxytryptamine2A receptor. Ser3.36(159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin
84. Site-directed mutagenesis of the 5-HT1B receptor increases the affinity of 5-HT for the agonist lowaffinity conformation and reduces the intrinsic activity of 5-HT
85. Chimeras of alpha1-adrenergic receptor subtypes identify critical residues that modulate active state isomerization
86. Molecular mechanisms of ligand binding and activation in alpha 1-adrenergic receptors
87. Lysine200 located in the fifth transmembrane domain of the histamine H1 receptor interacts with histamine but not with all H1 agonists
88. CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors
89. Mutations of transmembrane IV and V serines indicate that all tryptamines do not bind to the rat 5-HT2A receptor in the same manner
90. Site-directed mutagenesis of the human dopamine D2 receptor
91. Mutagenesis of residues adjacent to transmembrane prolines alters D1 dopamine receptor binding and signal transduction
92. Site-directed mutagenesis on the m2 muscarinic acetylcholine receptor: The significance of Tyr403 in the binding of agonists and functional coupling
93. Structure-function analysis of the betaadrenergic receptor
94. Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor
95. Site-directed mutagenesis of the human 5-HT1B receptor
96. Identification of a key amino acid of the beta2-adrenergic receptor for high affinity binding of salmeterol
97. Analysis of neuroleptic binding affinities and potencies for the different human D2 dopamine receptor missense variants
98. Identification of residues important for ligand binding to the human 5-hydroxytryptamine 1A serotonin receptor
99. TinyGRAP database: A bioinformatics tool to mine G-protein-coupled receptor mutant data
100. A constitutively active mutant beta 2-adrenergic receptor is constitutively desensitized and phosphorylated
101. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model
102. Negative antagonists promote an inactive conformation of the beta 2-adrenergic receptor
103. Binding, gating, affinity and efficacy: The interpretation of structure-activity relationships for agonists and of the effects of mutating receptors
104. Mutation of an aspartate residue highly conserved among G-protein-coupled receptors results in nonreciprocal disruption of alpha 2-adrenergic receptor-G-protein interactions. A negative charge at amino acid residue 79 forecasts alpha 2A-adrenergic receptor sensitivity to allosteric modulation by monovalent cations and fully effective receptor/G-protein coupling.
105. An aspartate conserved among G-protein receptors confers allosteric regulation of alpha 2-adrenergic receptors by sodium
106. A reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin-releasing hormone receptor
107. The functional microdomain in transmembrane helices 2 and 7 regulates expression, activation, and coupling pathways of the gonadotropin-releasing hormone receptor
108. Related contribution of specific helix 2 and 7 residues to conformational activation of the serotonin 5-HT2A receptor
109. Functional role of the spatial proximity of Asp114(2.50) in TMH 2 and Asn332(7.49) in TMH 7 of the mu opioid receptor
110. A proposed structure for transmembrane segment 7 of G protein-coupled receptors incorporating an asn-Pro/Asp-Pro motif
111. Mutational analysis of the relative orientation of transmembrane helices I and VII in G protein-coupled receptors
112. Arrangement of transmembrane domains in adrenergic receptors. Similarity to bacteriorhodopsin
113. Interactions between conserved residues in transmembrane helices 1, 2, and 7 of the thyrotropin-releasing hormone receptor
114. Rhodopsin mutation G90D and a molecular mechanism for congenital night blindness
115. Functional interaction of transmembrane helices 3 and 6 in rhodopsin. Replacement of phenylalanine 261 by alanine causes reversion of phenotype of a glycine 121 replacement mutant
116. Long-range structural effects in a secondsite revertant of a mutant dihydrofolate reductase
117. Substitutedcysteine accessibility method
118. Electrostatic potential of the acetylcholine binding sites in the nicotinic receptor probed by reactions of binding-site cysteines with charged methanethiosulfonates
119. Cysteine and disulfide scanning reveals a regulatory alpha-helix in the cytoplasmic domain of the aspartate receptor
120. The first transmembrane segment of the dopamine D2 receptor: Accessibility in the binding-site crevice and position in the transmembrane bundle
121. A cysteine residue in the third membrane-spanning segment of the human D2 dopamine receptor is exposed in the binding-site crevice
122. Projection structure of rhodopsin
123. Arrangement of rhodopsin transmembrane alpha-helices
124. An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors
125. Three-dimensional representations of G protein-coupled receptor structures and mechanisms
126. Rhodopsin: The structural basis of molecular physiology
127. Comparative protein modelling by satisfaction of spatial restraints
128. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations
129. 5-Hydroxytryptamine 2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): Where structure meets function
130. The conformational switch in muscarinic acetylcholine receptors
131. Constitutive activity of a chimeric D2/D1 dopamine receptor
132. Identification of transmembrane regions critical for ligand binding to the human D3 dopamine receptor using various D3/D1 transmembrane chimeras
133. Chimeric alpha 2-,beta 2-adrenergic receptors: Delineation of domains involved in effector coupling and ligand binding specificity
134. Genetic transfer of a nonpeptide antagonist binding site to a previously unresponsive angiotensin receptor
135. Functional microdomains in G-protein-coupled receptors. The conserved argininecage motif in the gonadotropin-releasing hormone receptor
136. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin
137. Agonists induce conformational changes in transmembrane domains III and VI of the beta2 adrenoceptor
138. Activation of the beta2 adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6
139. Constitutive activation of the beta2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment
140. Structural basis of G protein-coupled receptor function
141. Agonist-specific coupling of a cloned Drosophila octopamine/tyramine receptor to multiple second messenger systems
142. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals
143. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus
144. G protein-coupled receptors. I. Diversity of receptor-ligand interactions
145. Ligand stabilization of the beta 2 adrenergic receptor: Effect of DTT on receptor conformation monitored by circular dichroism and fluorescence spectroscopy
146. The high affinity state of the beta 2-adrenergic receptor requires unique interaction between conserved and non-conserved extracellular loop cysteines
147. Identification of critical extracellular loop residues involved in alpha 1-adrenergic receptor subtype-selective antagonist binding
148. Chimeric receptor analysis of the ketanserin binding site in the human 5-hydroxytryptamine1D receptor: Importance of the second extracellular loop and fifth transmembrane domain in antagonist binding
149. Coupling of canine serotonin 5-HT(1B) and 5HT(1D) receptor subtypes to the formation of inositol phosphates by dual interactions with endogenous G(i/o) and recombinant G(alpha15) proteins
150. Role of the second extracellular loop of adenosine receptors in agonist and antagonist binding. Analysis of chimeric Al/A3 adenosine receptors
151. Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition
152. Structure. Rhodopsin sees the light
153. Role of acidic amino acids in the allosteric modulation by gallamine of antagonist binding at the m2 muscarinic acetylcholine receptor
154. Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors
155. Agonist binding and function at the human alpha(2A)-adrenoceptor: Allosteric modulation by amilorides
156. Allosteric interactions between the antagonist prazosin and amiloride analogs at the human alpha(1A)-adrenergic receptor
157. Characterization of the allosteric interactions between antagonists and amiloride analogues at the human alpha2A-adrenergic receptor
158. Regulation of D2 dopamine receptors by amiloride and amiloride analogs
159. Regulation of dopamine D2 receptors by sodium and pH
160. The binding-site crevice of the D4 dopamine receptor is coupled to three distinct sites of allosteric modulation
161. The third extracellular loop of the beta2-adrenergic receptor can modulate receptor/G protein affinity